All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-09-11T14:17:04.000Z

Vididencel received fast track designation from the U.S. FDA

Sep 11, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in AML.

On September 8, 2023, vididencel, an off-the-shelf, intradermal vaccine, received fast track designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute myeloid leukemia (AML) in complete remission (CR) with residual disease.1 Vididencel was also previously granted orphan drug designation for the treatment of patients with AML in the U.S. and Europe.1

This fast track designation is based on results from the phase II ADVANCE II trial (NCT03697707) assessing vididencel monotherapy as a maintenance therapy for patients with AML in CR following chemotherapy, but with measurable residual disease (MRD).1,2 Results demonstrated that vididencel has the potential to control MRD and induce durable relapse-free survival.1 Vididencel will also be evaluated in combination with oral azacitidine in an upcoming phase II trial.1

  1. Mendus AB. Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML). https://mendus.com/news/mendus-receives-u-s-fda-fast-track-designation-for-vididencel-in-acute-myeloid-leukemia-aml. Published Sept 8, 2023. Accessed Sept 11, 2023.
  2. Mendus AB. Mendus AB: Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting. https://mendus.com/news/mendus-ab-mendus-presents-positive-survival-data-from-the-advance-ii-trial-evaluating-dcp-001-as-a-maintenance-therapy-in-aml-at-the-american-society-of-hematology-ash-meeting. Published Dec 13, 2022. Accessed Sept 11, 2023.

Newsletter

Subscribe to get the best content related to AML delivered to your inbox